Loading
A phase 2 trial of Atirmociclib, Letrozole, Fulvestrant in prostate cancer, run by Pfizer, active and no longer recruiting.
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors is a phase 2 interventional study registered as NCT04557449 by Pfizer, with 362 participants enrolled, started 2020-09-23 and due to reach its primary completion in 2026-09-23. Interventions recorded: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide. Conditions listed: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atirmociclib, Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/